5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright
New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, BPMC, CRSP, FOLD and VRNA well in this volatile sector.
| Ticker |
Sentiment |
Impact |
|
FOLD
|
Somewhat Bullish
|
8 %
|
|
VRNA
|
Neutral
|
5 %
|
|
VRTX
|
Neutral
|
3 %
|
|
EXEL
|
Somewhat Bullish
|
8 %
|
|
BPMC
|
Neutral
|
5 %
|
|
GILD
|
Neutral
|
3 %
|
|
LBPH
|
Neutral
|
3 %
|
